The Question

By carrying out this case study, we wanted
to know: Can technology driven patient
communities truly work towards driving
engagement and adherence?

The Challenge

A global pharmaceutical brand partnered with
RxPx to help solve the challenge of therapy
discontinuation. Clinical trials showed a 50%
discontinuation of this pharmaceutical brand s
therapy within the first 8 weeks. This was
attributed to several challenges: difficulty staying
adherent to 2x daily oral oncolytic, older age of
the patient population (average age range of 65
74), and side effects.

Click to read the full case study and find out about how 

RxPX powered this major global pharma brand to launch

an app-based patient community.
Read the Case Study

The Results

%

97% of patients remained
in app for at least 90
days, compared to
industry average of
31%**

%

70% of patients remained
in app for at least 1 year,
compared to industry
average of 18%**

%

52% of patients launch the
app 10 times or more in 30
days, compared to industry
average of 17%**